L
Leslie G. Ford
Researcher at National Institutes of Health
Publications - 90
Citations - 21684
Leslie G. Ford is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 41, co-authored 87 publications receiving 19931 citations. Previous affiliations of Leslie G. Ford include University of Texas Health Science Center at San Antonio & Walter Reed Army Institute of Research.
Papers
More filters
Journal ArticleDOI
Design of the Prostate Cancer Prevention Trial (PCPT)
Polly Feigl,Brent A. Blumenstein,Ian M. Thompson,John Crowley,Michael Wolf,Barnett S. Kramer,Charles A. Coltman,Otis W. Brawley,Leslie G. Ford +8 more
TL;DR: The PCPT design is described with reference to alternatives that were considered and the chosen design depends on five critical assumptions that must be monitored closely throughout the 9-year trial.
Journal ArticleDOI
The effect of age on the care of women with breast cancer in community hospitals.
Joseph Chu,Joseph Chu,Paula Diehr,Paula Diehr,Polly Feigl,Polly Feigl,Gwen Glaefke,Colin B. Begg,Arvin S. Glicksman,Leslie G. Ford +9 more
TL;DR: There was a linear trend for older patients to receive fewer services but other age patterns also were found, and age was not significantly associated with clinical staging or estrogen receptors.
Journal ArticleDOI
Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer
Chungyeul Kim,Gong Tang,Katherine L. Pogue-Geile,Joseph P. Costantino,Frederick L. Baehner,Joffre B. Baker,Maureen T. Cronin,Drew Watson,Steven Shak,Olga L. Bohn,Debora Fumagalli,Yusuke Taniyama,Ahwon Lee,Megan L. Reilly,Victor G. Vogel,Worta McCaskill-Stevens,Leslie G. Ford,Charles E. Geyer,D. Lawrence Wickerham,Norman Wolmark,Soonmyung Paik +20 more
TL;DR: Gen expression profiling of paraffin-embedded tumors from National Surgical Adjuvant Breast and Bowel Project trials that tested the worth of tamoxifen as an adjuvant systemic therapy and as a preventive agent suggest that low-level expression of ESR1 is a determinant of tamxifen resistance in ER-positive breast cancer.
Journal ArticleDOI
Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention
M. Scott Lucia,Amy K. Darke,Phyllis J. Goodman,Francisco G. La Rosa,Howard L. Parnes,Leslie G. Ford,Charles A. Coltman,Ian M. Thompson +7 more
TL;DR: The effectiveness of finasteride in preventing prostate cancer, including Gleason score ≤6 cancer, with meaningful rates of significant disease in the PCPT suggests that cutoff values for PSA screening should be individualized and that men undergoing screened should be informed of the opportunity to reduce their risk of disease with finasterid.
Journal ArticleDOI
A Nutrient Approach to Prostate Cancer Prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
TL;DR: Data show that neither selenium nor vitamin E, alone or together, in the doses and formulations used, prevented prostate cancer in this heterogeneous population of healthy men.